You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家醫保局:國家組織藥品集採已開展6批共採購234種藥品
國新辦召開政策例行吹風會,國家醫保局副局長陳金甫表示,國家組織藥品集採已開展6批,共採購234種藥品,涉及市場金額佔公立醫療機構化學藥和生物藥採購金額約30%,首六批藥品集採平均降價53%,心臟支架平均降價93%,人工髖、膝關節平均降價82%。截至2021年底,國家組織藥品和高值醫用耗材集採已累計節約費用超過2,600億元人民幣。 他表示,2021年開展胰島素專項採購,首次將集採從化學藥拓展到生物藥領域,高值醫用耗材集採將聚焦心內科及骨科兩個群眾最為關注的領域。另外心臟支架集採已平穩運行一年,中選支架使用總量169萬個,達到全年協議採購量近1.6倍,去年亦針對較為複雜的骨科耗材開展國家組織人工關節集採。 國家醫保局將常態化、制度化開展藥品和高值醫用耗材集中帶量採購,預期至2022年底實現國家及省級集採藥品合計數在每個省份均達到350個以上,高值醫用耗材品種數達到5個以上。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account